Delaying Rheumatoid Arthritis Monotherapy Adversely Affects Outcome

NEW YORK (Reuters Health) Apr 01 – Prospective study results released today demonstrate that remission of rheumatoid arthritis is compromised when initial treatment with a single disease-modifying antirheumatic drug (DMARD) is delayed by a few months, but not when combination treatment is delayed.
"Our data suggest that the combination of DMARDs as an initial therapy in early RA should be considered more frequently than it is at present," the investigators write in the April issue of Arthritis & Rheumatism.

לכתבה המלאה

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים